ASHBURN, Va., March 11, 2026 (GLOBE NEWSWIRE)-- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on developing and ...

Quoin Pharmaceuticals Ltd. has filed a U.S. patent application for new topical formulations aimed at treating several skin diseases, specifically Netherton Syndrome (NS) and Peeling Skin Syndrome. The ...

Detailed price information for Quoin Pharmaceuticals Ltd ADR (QNRX-Q) from The Globe and Mail including charting and trades.

Initial pediatric subject shows sustained benefit with QRX003; second patient approved for full-body treatment in ongoing Netherton syndrome study ASHBURN, VA, April 2, 2025 (EZ Newswire) -- Quoin ...

Quoin Pharmaceuticals Ltd. announced the launch of its "Living with Netherton" video series, aimed at raising awareness about Netherton Syndrome, a poorly understood genetic disease. The first episode ...

ASHBURN, Va., May 20, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on rare and orphan diseases ...

Target Indications Also Include Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma and Severe Atopic Dermatitis Third Quoin Patent Application for Netherton Syndrome If Granted Company ...

Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--LifeMax Laboratories, Inc. (“LifeMax”), a private company focused on developing first-in-class or best-in-class therapeutics for the treatment of orphan diseases ...

Our skin has two crucial barrier functions: it protects against water loss and it prevents penetration of infectious agents and allergens. By studying mice and humans, a team of researchers in France ...

— Fast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditions with significant unmet medical need — — QRX003 lotion (4%) currently being ...

— QRX003 lotion (4%) currently being evaluated in two late-stage whole-body clinical trials for treatment of Netherton Syndrome — — Fast Track Designation follows Pediatric Rare Disease and Orphan ...